RPG Life Sciences Limited
All news and filings related to RPG Life Sciences Limited.
View all news & filings- Medium impact
RPG Life Sciences Subsidiary RPGAP Allots Shares Worth ₹243.33 Cr to ILSF & VJF
RPG Life Sciences' subsidiary, RPGAP, has allotted securities to ILSF and VJF for ₹243.33 crores, representing 40% equity. RPGAP remains a subsidiary of RPG Life Sciences.
Read the summary - Low impact
RPG Life Sciences Provides Update on Analyst/Institutional Call Held Sept 3
RPG Life Sciences Limited provided an update on an Analyst/Institutional call held on September 3, 2026. Details from the call are now available on the company's website. This follows prior communications on September 2 and 3, 2026.
Read the summary - Low impact
RPG Life Sciences Invites Analysts/Investors to API Business Update Call on Sep 3
RPG Life Sciences Limited will host an API business update call for analysts and institutional investors on September 03, 2026, at 4:00 PM IST. Key management, including the Managing Director and CFO, will present. Dial-in details are provided for participation.
Read the summary - High impact
RPG Life Sciences Unveils Major Strategic Moves: API Business Transfer, PE Investment, and Acquisitions
RPG Life Sciences is transferring its API business to RPGAP and partnering with InvAscent for ₹243.33 crore. It's also acquiring Actis Generics for ~₹80 crore and Raghava Life Sciences for ~₹135 crore to enhance its product portfolio and capacity. These moves aim to accelerate value creation and growth.
Read the summary - Low impact
RPG Life Sciences to Host Investor Call on Sep 3, 2026
RPG Life Sciences will host a virtual investor and analyst call on September 3, 2026, at 4:00 PM IST. This follows a strategic announcement made on September 2, 2026. Dial-in details and investor presentations will be shared separately.
Read the summary - High impact
RPG Life Sciences subsidiary acquires Raghava's API business for up to ₹135 crore
RPG Life Sciences' subsidiary, RPG Active Pharma, will acquire Raghava Life Sciences' API and Intermediates business for up to ₹135 crore. The deal includes a EU-GMP approved manufacturing facility and a portfolio of 22 commercialized APIs. This is RPGAP's second strategic acquisition, aimed at building a scaled API business.
Read the summary - Medium impact
RPG Life Sciences to Acquire API Business of Raghava Life Sciences for ₹135 Crore
RPG Life Sciences' subsidiary will acquire the API and Intermediates Business of Raghava Life Sciences for up to ₹135 Crore via slump sale. The acquired business had revenues of ₹19 Crore in FY26 and includes manufacturing facilities and 29 API molecules. The deal is expected to close within 30 days.
Read the summary - High impact
RPG Life Sciences to Acquire API Business of Raghava Life Sciences for ₹135 Crore
RPG Life Sciences' subsidiary will acquire the API and intermediates business of Raghava Life Sciences via slump sale for up to ₹135 crore. The acquired business had FY26 revenues of ₹19 crore and includes manufacturing, R&D facilities, and 29 API molecules. This aligns with the company's strategy to expand its API segment.
Read the summary - Low impact
RPG Life Sciences Cancels Investor Meet Scheduled for September 2, 2026
RPG Life Sciences Limited has cancelled its Investors/Analysts meet that was scheduled for September 2, 2026. This cancellation was communicated on September 1, 2026, referencing a prior notice from August 25, 2026.
Read the summary - Low impact
RPG Life Sciences to Participate in Ashwamedh – Elara India Dialogue 2026
RPG Life Sciences Limited will participate in the Ashwamedh – Elara India Dialogue 2026 investor meet. The event, a group meet and one-on-one session, is scheduled for September 02, 2026, starting at 10:00 A.M. IST in Mumbai. The date is subject to change.
Read the summary - Low impact
RPG Life Sciences to Participate in Antique Healthcare Investor Conference on Aug 25
RPG Life Sciences Limited will attend the Antique Healthcare Investor Conference 2026 on August 25, 2026, in Mumbai. The event is a physical group meet. The date is subject to change.
Read the summary - Low impact
RPG Life Sciences: Deepak Shukla Ceases as Senior Management, Moves to Subsidiary
Mr. Deepak Shukla has ceased to be Senior Management Personnel at RPG Life Sciences Limited as of August 14, 2026. He will assume the role of Chief Executive Officer at RPG Active Pharma Limited, a subsidiary, starting August 15, 2026.
Read the summary - Low impact
RPG Life Sciences Completes API Business Transfer to Subsidiary Effective Aug 15, 2026
RPG Life Sciences Limited has completed the transfer of its Active Pharmaceuticals Ingredients (API) Business to its wholly owned subsidiary, RPG Active Pharma Limited. The transaction, conducted on a slump sale basis, is effective from August 15, 2026.
Read the summary - Medium impact
RPG Life Sciences Invests ₹65.69 Cr in Wholly Owned Subsidiary RPGAP
RPG Life Sciences invested up to ₹65.69 Crores in its wholly owned subsidiary, RPG Active Pharma Limited (RPGAP), via a rights issue. This investment maintains RPG Life Sciences' 100% shareholding in RPGAP, which is yet to commence operations. The shares were allotted on August 14, 2026.
Read the summary - Low impact
RPG Life Sciences to Participate in Emkay Confluence 2026 on August 13
RPG Life Sciences Limited will attend the Emkay Confluence 2026, a physical group meet in Mumbai on August 13, 2026. The company's participation is for investor engagement. The date is subject to change.
Read the summary - Low impact
RPG Life Sciences: VP Sales & Marketing Samir Rane Retires, Ceases Senior Management Role
Mr. Samir Rane, Vice President of Sales & Marketing at RPG Life Sciences Limited, has retired and ceased to be Senior Management Personnel. His cessation is effective July 31, 2026, due to attaining the age of superannuation.
Read the summary - Low impact
RPG Life Sciences Announces Special Window for Demat Requests
RPG Life Sciences opens a special window for demat requests of physical securities transacted before April 1, 2019. Advertisements were published on July 31, 2026. This aims to facilitate the transfer and dematerialisation process for eligible securities.
Read the summary - Low impact
RPG Life Sciences Publishes Q1 FY27 Unaudited Financial Results
RPG Life Sciences Limited has published its unaudited financial results for the quarter ended June 30, 2026. The results were announced on July 29, 2026, and are available on the company website. A separate notice regarding Rallis India Limited's share transfer window is also included.
Read the summary - High impact
RPG Life Sciences Q1 FY27: Revenue Grows 15.8% to ₹195.7 Cr, PAT Up 17.0% to ₹30.8 Cr
RPG Life Sciences reported Q1 FY27 results with revenue up 15.8% to ₹195.7 crore and PAT up 17.0% to ₹30.8 crore. Domestic Formulations grew 14.8%, APIs by 35.6%, and International Formulations by 7.7%. The company aims to scale core brands and expand its specialty and API businesses.
Read the summary - Medium impact
RPG Life Sciences Q1 FY27 Revenue up 15.8% to ₹195.7 Cr; EBITDA grows 17.9%
RPG Life Sciences reported Q1 FY27 revenue of ₹195.7 Cr, a 15.8% increase year-on-year. EBITDA grew 17.9% to ₹48.0 Cr, with margins expanding to 24.5%. Domestic Formulations grew 14.8%, outpacing the market. The company entered the Top 50 Indian Pharma Companies list.
Read the summary - Medium impact
RPG Life Sciences Q1 FY27 Results: Revenue ₹19,985 Lakhs, Profit ₹3,057 Lakhs
RPG Life Sciences reported unaudited financial results for Q1 FY27. Standalone revenue was ₹19,985 lakhs, with a profit of ₹3,057 lakhs. Consolidated revenue was ₹20,039 lakhs, with a profit of ₹3,076 lakhs. EPS stood at ₹18.49 (standalone) and ₹18.60 (consolidated). The Board also approved the transfer of the API division to a subsidiary.
Read the summary - Low impact
RPG Life Sciences: Independent Director Ms. Zahabiya Khorakiwala Completes Tenure
Ms. Zahabiya Khorakiwala, an Independent Director at RPG Life Sciences Limited, has completed her second consecutive five-year term, ending on July 26, 2026. Consequently, she will step down from the Sustainability and Corporate Social Responsibility Committee.
Read the summary - Medium impact
RPG Life Sciences AGM: All resolutions passed including ₹24 dividend
RPG Life Sciences Limited's 19th AGM on July 23, 2026, saw all resolutions passed. Key approvals include the FY26 financial statements and a ₹24 per share dividend. Mr. Harsh V. Goenka and Mr. Manoj Maheshwari were re-appointed as directors, and Dr. Pratit Samdani appointed as Independent Director for a five-year term.
Read the summary - Medium impact
RPG Life Sciences AGM: All resolutions passed, including dividend declaration.
RPG Life Sciences Limited's Nineteenth AGM on July 23, 2026, saw all resolutions passed. Key approvals include the FY26 financial statements, a ₹24 per share dividend, director re-appointments, and the appointment of Dr. Pratit Samdani as an Independent Director until April 2031. The meeting concluded with unanimous support for all agenda items.
Read the summary - Medium impact
RPG Life Sciences Partners Archerchem for Naprosyn ES Launch in India
RPG Life Sciences has partnered with Archerchem Healthcare to launch Naprosyn ES, a combination of Naproxen and Esomeprazole, in India. RPG LS will market and distribute the product exclusively, while Archerchem will be the exclusive supplier. This launch aims to provide safer long-term pain management and improve patient compliance.
Read the summary - Low impact
RPG Life Sciences Cancels Erroneous Record Date for Final Dividend
RPG Life Sciences Limited erroneously stated June 19, 2026, as the record date for final dividend payment on the NEAPS portal. The company has requested cancellation of this date. A new record date will be announced after the AGM date is finalized.
Read the summary - Low impact
RPG Life Sciences Limited Clarifies No Material Event for Volume Surge
RPG Life Sciences Limited clarified to the NSE that there are no unpublished material events or information that could explain the recent surge in trading volume. The company attributes the volume increase to market conditions.
Read the summary - Low impact
RPG Life Sciences: Notice on Transfer of Equity Shares to IEPF Account
RPG Life Sciences is transferring unclaimed shares to the IEPF Account. Shareholders with unclaimed dividends since FY 2018-19 must claim them by September 01, 2026. Failure to do so will result in share transfer to IEPF. The company has published notices and updated its website with relevant details.
Read the summary - Low impact
RPG Life Sciences to present at RPG Annual Investor Conference 2026 on May 26
RPG Life Sciences will present at the RPG Annual Investor Conference 2026 on May 26, 2026. The company reported FY26 revenue of ₹707.5 crore, EBITDA of ₹172.7 crore, and EPS of ₹69.6. Its Domestic Formulations business outperformed the market, growing 1.6x faster than IPM. Investments of over ₹185 crore in capex were made over five years.
Read the summary - Low impact
RPG Life Sciences to Host Annual Investor Conference on May 26, 2026
RPG Life Sciences Limited will host its Annual Investor Conference on May 26, 2026. The event will be an in-person one-on-one and group meeting. No unpublished price sensitive information will be disclosed.
Read the summary - Low impact
RPG Life Sciences Q4 FY26 Earnings Call Transcript Released
RPG Life Sciences Limited released the transcript for its Q4 FY26 earnings call, which discussed financial results for the quarter and year ended March 31, 2026. The call took place on April 30, 2026. The transcript is available on the company's website.
Read the summary - Medium impact
RPG Life Sciences Approves ₹24 Dividend, Appoints New Director
RPG Life Sciences announced audited financial results for the quarter and year ended March 31, 2026. The Board recommended a dividend of ₹24 per share. Dr. Pratit Samdani was appointed as an Additional Non-Executive Independent Director for five years. Amendments to the trading code were also approved.
Read the summary - Low impact
RPG Life Sciences Q4 FY26 Earnings Call Audio Recording Available
RPG Life Sciences Limited has made the audio recording of its Q4 FY26 earnings call available. The call, held on April 30, 2026, discussed audited financial results for the quarter and year ended March 31, 2026. The recording is accessible on the company's website.
Read the summary - Low impact
RPG Life Sciences Publishes Audited Financial Results for Q4FY26
RPG Life Sciences Limited announced its audited financial results for the quarter and year ended March 31, 2026. The results were published in newspapers on April 30, 2026, and are also available on the company's website. This is a routine disclosure as per SEBI regulations.
Read the summary - High impact
RPG Life Sciences Presents Investor Presentation for Q4 and FY26 Results
RPG Life Sciences reported Q4 FY26 revenue growth of 23.6% and PAT growth of 58.1% (excl. exceptional items). Full-year FY26 revenue reached ₹707.5 crore. The company is focused on scaling core brands, expanding its specialty portfolio, and strengthening its API business. ICRA reaffirmed its A+ rating.
Read the summary - Medium impact
RPG Life Sciences Board Approves FY26 Audited Results, Recommends ₹24 Dividend
RPG Life Sciences approved FY26 audited standalone and consolidated financial results for the quarter ended March 31, 2026. The board recommended a dividend of ₹24 per share. Dr. Pratit Samdani was appointed as an Additional Non-Executive Independent Director for five years.
Read the summary - Medium impact
RPG Life Sciences Board Approves FY26 Results, Recommends ₹24 Dividend, Appoints New Director
RPG Life Sciences announced its audited financial results for the quarter and year ended March 31, 2026. The board recommended a dividend of ₹24 per share for FY26, subject to shareholder approval. Dr. Pratit Samdani was appointed as an Additional Non-Executive Independent Director for five years.
Read the summary - Medium impact
RPG Life Sciences Board Approves FY26 Audited Results, ₹24 Dividend, Appoints Director
RPG Life Sciences approved audited financial results for the quarter and year ended March 31, 2026. The Board recommended a dividend of ₹24 per share for FY26. Dr. Pratit Samdani was appointed as an Additional Non-Executive Independent Director for a five-year term starting April 29, 2026.
Read the summary - High impact
RPGLIFE Q4 FY26 Revenue up 23.6% to ₹176.9 Cr, Recommends 300% Dividend
RPG Life Sciences reported Q4 FY26 revenue of ₹176.9 crore, up 23.6% YoY, with an EBITDA margin of 25.6%. For FY26, revenue grew 8.3% to ₹707.5 crore. The DF business grew 18.2% in Q4 and 13.7% for FY26. The API division grew 144.3% in Q4. The company recommended a 300% dividend (₹24 per share).
Read the summary - Medium impact
RPG Life Sciences Board Approves FY26 Audited Results, Recommends ₹24 Dividend, Appoints New Director
RPG Life Sciences approved audited financial results for FY26 and recommended a dividend of ₹24 per share. Dr. Pratit Samdani was appointed as Additional Non-Executive Independent Director for five years. Amendments were also made to the trading code.
Read the summary - Medium impact
RPG Life Sciences recommends ₹24 dividend; appoints Dr. Pratit Samdani as Director
RPG Life Sciences approved audited financial results for the quarter and year ended March 31, 2026. The Board recommended a dividend of ₹24 per share for FY 2025-26. Dr. Pratit Samdani was appointed as an Additional Non-Executive Independent Director for five years.
Read the summary - Low impact
RPG Life Sciences Schedules Q4 FY26 Earnings Conference Call for April 30, 2026
RPG Life Sciences will host its Q4 FY26 earnings conference call on April 30, 2026, at 3:30 PM IST. The call will cover audited financial results for the period ending March 31, 2026. Key management personnel will be present.
Read the summary - Low impact
RPG Life Sciences Files SEBI Compliance Certificate for Q4FY26
RPG Life Sciences Limited received a compliance certificate from its Registrar and Transfer Agents, MUFG Intime India Private Limited. The certificate confirms adherence to SEBI (Depositories and Participants) Regulations, 2018 for the quarter ending March 31, 2026, regarding the dematerialisation of securities.
Read the summary - Low impact
RPG Life Sciences: Newspaper Publication on Special Window for Demat Requests
RPG Life Sciences Limited has published newspaper advertisements about a special window for demat requests of physical securities sold before April 1, 2019. This action complies with a SEBI circular and was announced in Business Standard and Mumbai Lakshadeep on April 7, 2026. Details will also be on the company's website.
Read the summary - Low impact
RPG Life Sciences Launches 'Saksham Niveshak' Campaign for Shareholders
RPG Life Sciences is participating in the 'Saksham Niveshak' campaign to help shareholders claim unpaid dividends and update KYC. This initiative, launched by IEPFA, encourages shareholders to provide updated bank mandates and nominations to avoid dividend transfer to IEPF. Shareholders can submit documents physically or via email.
Read the summary - Low impact
RPG Life Sciences: Trading Window Closed for FY26 Audited Results
RPG Life Sciences Limited will close its trading window from April 1, 2026. The window will reopen 48 hours after the declaration of audited financial results for the fiscal year ending March 31, 2026. The board meeting date for results declaration will be announced later.
Read the summary - Low impact
RPG Life Sciences: Special Window for Physical Share Transfer & Dematerialisation
RPG Life Sciences opens a special window for physical share transfer and dematerialisation. Applicable for shares lodged before April 1, 2019, and rejected/returned due to deficiencies. The window is open from February 5, 2026, to February 4, 2027. Shareholders must submit requests to the Registrar and Transfer Agent.
Read the summary - Medium impact
RPG Life Sciences Q3FY26 Results: Profit Before Tax at ₹291 Crore, API Division Transfer in Progress
RPG Life Sciences reported Q3FY26 standalone and consolidated Profit Before Tax of ₹2.91 crore. The company is transferring its API division to a subsidiary, RPG Active Pharma Limited, expected to conclude by February 2026. Exceptional expenses include ₹8.42 crore for Q3FY26, comprising a net fire incident loss and ₹11.08 crore impact from New Labour Codes.
Read the summary - Medium impact
RPG Life Sciences Signs Power Agreement and Invests ₹1.5 Crore
RPG Life Sciences has signed a Captive Power Agreement and Share Subscription Agreement with First Energy 11 Private Limited. The company will invest up to ₹1.5 crore to secure power from a wind-solar hybrid plant for its Ankleshwar facility. This investment will give RPG Life Sciences a stake in the power producer.
Read the summary - Low impact
RPG Life Sciences Publishes Q3FY26 Unaudited Financial Results
RPG Life Sciences Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The results were published in Business Standard and Mumbai Lakshadeep on January 28, 2026, and are available on the company's website.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio